Cargando…
Effect of peritoneal dialysis fluid containing osmo-metabolic agents on human endothelial cells
BACKGROUND: The use of glucose as the only osmotic agent in peritoneal dialysis (PD) solutions (PDSs) is believed to exert local (peritoneal) and systemic detrimental actions, particularly in diabetic PD patients. To improve peritoneal biocompatibility, we have developed more biocompatible PDSs cont...
Autores principales: | Bonomini, Mario, Di Silvestre, Sara, Di Tomo, Pamela, Di Pietro, Natalia, Mandatori, Domitilla, Di Liberato, Lorenzo, Sirolli, Vittorio, Chiarelli, Francesco, Indiveri, Cesare, Pandolfi, Assunta, Arduini, Arduino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135076/ https://www.ncbi.nlm.nih.gov/pubmed/27932866 http://dx.doi.org/10.2147/DDDT.S117078 |
Ejemplares similares
-
The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis
por: Bonomini, Mario, et al.
Publicado: (2020) -
Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis
por: Palmerini, Carola, et al.
Publicado: (2021) -
Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis
por: Bonomini, Mario, et al.
Publicado: (2019) -
Proteomic Research in Peritoneal Dialysis
por: Bonomini, Mario, et al.
Publicado: (2020) -
A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience
por: Rago, Carmela, et al.
Publicado: (2021)